Zurück zu den Rankings

Henry Schein, Inc. (HSIC)

Fair bewertet
HealthcareMedical DistributionUnited States

Fundamental

58

Kurs

$84.64

Marktkapitalisierung

$9.57B

Teil 1 · Was das Unternehmen wert ist

Übersicht

Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as provides equipment repair services, financial services on a non-recourse basis, continuing education services for practitioners, consulting, and other services. It also markets and sells a portfolio of consumable merchandise under its own corporate brand. The Global Specialty Products segment engage in manufacturing, marketing, and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products, and other health care-related products and services. The Global Technology segment is involved in the development and distribution of practice management software, e-services, and other products which are distributed to health care providers. The company serves dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics, home health providers, and other alternate care clinics. It has a strategic partnership with GoTu Technology to help dental practices address ongoing staffing challenges. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

Compare

Generated on 18. September 2026 with claude-haiku-4-5 — shared with all users

P/E: 22.9Score: 78Market cap: $99.84B

Cited by Henry Schein as one of two national competitors in medical distribution, McKesson supplies the same office-based physicians and alternate-care sites with pharmaceuticals and medical-surgical products.

P/E: 32.0Score: 76Market cap: $51.78B

Its Medical segment distributes surgical and examination supplies to physician offices, ambulatory surgery centers and home-care providers, the same alternate-care customers Henry Schein Medical serves.

Patterson Companies, Inc. (Patterson Dental)Not tracked

Named in Henry Schein's 10-K as its main U.S. rival, Patterson Dental sells the same consumables, equipment and practice-management software to the same dental offices, and has been privately held since Patient Square Capital took it off Nasdaq in April 2025.

Benco Dental Supply CompanyNot tracked

The third full-service dental distributor in the United States, family-owned and unlisted, competing with Henry Schein practice by practice for the same dental supply and equipment budgets.

Medline Industries, LPNot tracked

The other national medical competitor named in the 10-K, privately held, selling medical-surgical supplies to the same physician practices, surgery centers and long-term care facilities.

Bilanz & Liquidität

Umsatz

$13.60B

Letzte 12 Monate (bis 27.6.2026)

Nettogewinn

$403M

Letzte 12 Monate (bis 27.6.2026)

Freier Cashflow

$573M

Gesamtes Eigenkapital

$3.25B

Gesamtverbindlichkeiten

$6.42B

Current Ratio

1.32

Zinsdeckungsgrad

4.28

Schulden/EBITDA

3.96

Gewinn je Aktie

Umsatz & Nettogewinn

Freier Cashflow

Ertragsaufschlüsselung

Historische Aufstellung

Margen im Zeitverlauf

Verschuldung im Zeitverlauf

Wie schwer die Schulden wiegen

Wachstumsraster

Wachstum — Umsatz

Innerer-Wert-Schätzung

Allgemeiner FallFair bewertet

Innerer Wert

$77.47

Aktueller Kurs

$84.64

Sicherheitsmarge

-9.2%

Innerer-Wert-Spanne

$53.98 - $100.95

Streubreite zwischen den verwendeten Bewertungsmethoden, kein statistisch kalibriertes Konfidenzintervall.

Bewertungsmethoden

Kursziel der Analysten:$97.27
Diskontierter Cashflow (DCF):$97.21
Gewinnmultiplikator (P/E):$51.61
Graham-Wachstumsformel:$43.59
Ertragskraftwert (EPV):$50.50
Gerechtfertigtes P/B:$40.68
Dividendendiskontierung (Gordon):Nicht genügend Daten zur Berechnung
P/FFO, Funds from Operations:$101.79
Gewinn im Zyklusmittel:$164.55
Umsatzmultiplikator:$468.49
Analystenkonsens:Kaufen (15B / 9H / 1S)
Letzte Gewinnüberraschung:+0.67%

Bewertungskennzahlen

P/E-Verhältnis

24.48

ROE

12.3%

P/B-Verhältnis

2.96

P/FCF

16.45

Bruttomarge

31.3%

ROIC

6.8%

Rentabilitäts-Radar

Wertschöpfung (Wettbewerbsvorteil)

ROIC

6.8%

WACC

7.5%

ROIC − WACC

-0.7 pp

Der ROIC liegt etwa auf Höhe der Kapitalkosten: Das Unternehmen deckt gerade eben seine Kapitalkosten.

Fundamentalanalyse-Kriterien

Bestanden (18)

  • EPS shows upward trend
  • ROIC 6.8%
  • Gross Margin 31.3%
  • P/FCF 16.45
  • P/B Ratio 2.96
  • Debt/Equity ratio
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 12.4%
  • Revenue Growth 5Y 5.4%
  • Analyst Consensus 60% Buy
  • Earnings Surprise avg 3.5%
  • Earnings Quality (OCF/NI) 1.74
  • Share Dilution -4.8%

Nicht bestanden (9)

  • EPS CAGR 1.29%
  • Price CAGR 3.64%
  • Operating Margin 5.0%
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Fairly valued)
  • PEG Ratio 7.91
  • Net Margin Trend 3.0% vs 3.0%
  • Piotroski F-Score 4/9

Nicht verfügbar (1)

  • Dividend Payout NaN%

Piotroski F-Score

4/9

Gemischte Signale: Einige Bereiche bedürfen Aufmerksamkeit

score
criteria

Gewinnqualität

1.74

Hohe Qualität: Gewinne durch Cashflow gedeckt

Aktienverwässerung

-4.8%

Aktienrückkäufe. Aktionärsfreundlich

Institutionelle Beteiligungen

Unternehmensführung

Führungsteam

NamePositionAlter
Mr. Ronald N. SouthSenior VP & CFO63
Mr. Michael Saul EttingerExecutive VP & COO64
Mr. Mark E. MlotekExecutive VP & Chief Strategic Officer69
Mr. Andrea AlbertiniChief Executive Officer of Global Distribution & Technology55
Mr. Frederick M. LoweryCEO & Director54
Ms. Olga TimoshkinaVP of Corporate Finance & Chief Accounting Officer-
Mr. Christopher PendergastSenior VP & CTO62
Mr. Graham StanleyVP of Investor Relations & Strategic Finance Project Officer-
Ms. Kelly Murphy J.D.Senior VP & General Counsel44
Ms. Christine SheehySenior VP & Chief Human Resources Officer57

Prüfungsrisiko

4

Vorstandsrisiko

8

Vergütungsrisiko

6

Aktionärsrechterisiko

4

Teil 2 · Der Preis und der Einstiegszeitpunkt

Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.

Dokumente

  • Jahresbericht (10-K)

    Ein jährlicher Überblick über das Geschäft, die Finanzergebnisse und die Risiken des Unternehmens.

    Eingereicht am 2026-02-24

    Dokument ansehen
  • Quartalsbericht (10-Q)

    Ein Update zur finanziellen Entwicklung der letzten drei Monate.

    Eingereicht am 2026-08-04

    Dokument ansehen
  • Ad-hoc-Meldung (8-K)

    Eine Mitteilung über ein wichtiges Ereignis, etwa einen Führungswechsel oder eine bedeutende Ankündigung.

    Eingereicht am 2026-09-22

    Dokument ansehen

via SEC EDGAR

Ertragshistorie

via SEC EDGAR

Latest News

Recent headlines for HSIC, sourced from Markets Gazette.

  • 6/11/2026POSITIVE
    This Henry Schein Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

    Henry Schein Inc. (HSIC) has received a bullish upgrade from Wall Street analysts, signaling a potentially positive outlook for the company's stock. While specific details of the upgrade and the analysts' reasoning are not provided in this snippet, such a shift in sentiment typically suggests that analysts foresee improved financial performance, strategic advantages, or favorable market conditions for HSIC. Investors often view analyst upgrades as a catalyst for stock price appreciation, potentially leading to increased buying interest and upward price momentum.

  • 2/24/2026NEUTRAL
    Henry Schein (HSIC) Q4 2025 Earnings Transcript

    Investors in Henry Schein Inc. (HSIC) are poised to analyze the Q4 2025 earnings transcript, released on February 24, 2026. This event is pivotal for understanding the financial performance of the company, a global leader in distributing healthcare products and services to medical and dental practices. The report's analysis will provide crucial details on revenues, earnings per share (EPS), operating margins, and future outlook, which are fundamental elements for assessing the company's health and potential growth trajectories. While specific data is not yet available for direct evaluation, the transcript's release marks a key moment for the market, allowing deeper insight into management's statements and responses to analyst questions, thereby shaping expectations for the upcoming fiscal period and its impact on share value.

via Markets Gazette